Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELOBiotechnology
-$0.04 today
- Market cap
- $50.84M
- Beta
- -0.24
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.27
Volume 0.17M
Average 0.13M
TELO Other Current Assets
Current assets not reported separately, such as prepaid expenses.
Telomir Pharmaceuticals, Inc. Common StockNASDAQ: TELO
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets turns positive
Q1 FY2026 other current assets was $229.03K, compared with -$0 a year earlier.
Context
- Other current assets amounted to 4.0% of total assets at the end of Q1 FY2026, up 4.0 pp from a year earlier.
- Other current assets increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether other current assets keeps rising in the next quarterly balance sheet after a +537617370892018816.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $229.03K+119283854166666768.0% QoQ
- Last fiscal yearDec 2025
- -$0-177.1% YoY
- Year agoMar 2025
- -$0+537617370892018816.0% since
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- (0) USD
- Year-over-year change
- -177.1%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (0) | -177.1% |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 303.28K | +541.0% |
| FY2022 | 2022-12-31 | 47.31K | — |
| FY2021 | 2021-12-31 | 0 | — |
Other Current Assets vs competitors
How TELO compares with its peers on the latest reported figures
- TELO's Mar 2026 other current assets of $229.03K is the lowest of the 6 companies compared; the peer median is $953K.
- Its year-over-year change of +537617370892018816.0% is the highest of 5, against a peer median of +127.7%.
- Other current assets amounts to 4.0% of total assets for TELO, versus a peer median of 2.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $8.53M | -17.1% | -24.0% | 6.5% | |
| Mar 2026 | $4.24M | +20.1% | +86.3% | 1.3% | |
| Mar 2026 | $953K | +2547.2% | — | 1.5% | |
| Mar 2026 | $694K | +235.3% | — | 2.7% | |
| Mar 2026 | $631.08K | — | — | 3.2% | |
| Mar 2026 | $229.03K | +537617370892018816.0% | — | 4.0% | |
| Peer median (excluding TELO) | $953K | +127.7% | +31.2% | 2.7% | |
Competitors are the stored peer set for TELO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELO
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.